Compare Neurocrine Biosciences Inc (NBIX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Utilities Select Sector SPDR Fund — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Utilities Select Sector SPDR Fund trades at $42.95. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| NBIX | XLU | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | — |
52-Week High | $185.50 | $47.73 |
52-Week Low | $123.10 | $41.86 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
XLU trades at $43.45, up 0.86% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The utilities ETF faces conflicting narratives around AI power demand versus regulatory headwinds, with recent news highlighting both defensive appeal and concerns about concentrated AI exposure. Support levels cluster around $42-43 while resistance sits at $44.
The ETF's outlook balances defensive utility characteristics against AI-driven growth potential. Key opportunities include inflation hedging and dividend income, while risks center on regulatory intervention and uneven AI benefits across the portfolio. Current sentiment reflects cautious optimism as investors weigh utility stability against transformative power demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
